Fluticasone propionate intranasal - Paratek Pharmaceuticals
Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate; XHANCELatest Information Update: 23 May 2025
At a glance
- Originator OptiNose AS
- Developer Paratek Pharmaceuticals
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Nasal polyps; Rhinosinusitis
- No development reported Asthma
Most Recent Events
- 21 May 2025 OptiNose has been acquired and merged into Paratek Pharmaceuticals
- 27 Feb 2025 Optinose plans a phase III trial for Rhinosinusitis (In Children, In adolescents) in April 2025 (NCT06850805)
- 21 May 2024 Launched for Rhinosinusitis in USA (Intranasal)